Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-NYM032 in PSMA-Positive mCRPC
NCT06383052Phase 2Active, not recruiting
- Sponsor
- Norroy Bioscience
- Start
- Apr 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NY108 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Norroy Bioscience. Started Apr 2024; status: active, not recruiting.
02
Drugs
NY108
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06383052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06383052.